Signs Of Long-Term Efficacy Boost UniQure’s Hem B Gene Therapy
Will Await Main Study’s One-Year Milestone Before Submission
Unveiling its latest data, UniQure is tipped to avoid the knockback which affected BioMarin’s hemophilia A gene therapy, with a filing expected in the second half of 2021.
